Doxorubicin + Docetaxel + Cyclophosphamide [clinicaltrials_resource:NCT00003782/group/E3]
Doxorubicin + Docetaxel + Cyclophosphamide
Reported events for NCT00003782 [clinicaltrials_resource:944ce5d99abac83c0e226f24e94621c9]Total, other adverse events for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/other_events/58/count/174]Febrile neutropenia for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/other_events/59/count/177]Diarrhea for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/other_events/60/count/180]Nausea for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/other_events/61/count/183]Vomiting for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/other_events/62/count/186]Fatigue for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/other_events/63/count/189]Infections and infestations - Other, specify for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/other_events/64/count/192]Arthralgia for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/other_events/65/count/195]Myalgia for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/other_events/66/count/198]Total, serious adverse events for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/1/count/3]Duodenal ulcer for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/10/count/30]Esophagitis for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/11/count/33]Gastrointestinal disorders - Other, specify for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/12/count/36]Mucositis oral for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/13/count/39]Typhlitis for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/14/count/42]Vomiting for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/15/count/45]General disorders and administration site conditions - Other, specify for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/16/count/48]Hepatic failure for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/17/count/51]Hepatobiliary disorders - Other, specify for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/18/count/54]Anaphylaxis for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/19/count/57]Febrile neutropenia for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/2/count/6]Infections and infestations - Other, specify for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/20/count/60]Wound infection for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/21/count/63]Dermatitis radiation for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/22/count/66]Alanine aminotransferase increased (ALT/SGPT) for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/23/count/69]Aspartate aminotransferase increased (AST/SGOT) for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/24/count/72]Blood bilirubin increased for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/25/count/75]Creatinine increased for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/26/count/78]Neutrophil count decreased for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/27/count/81]White blood cell decreased for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/28/count/84]Anorexia for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/29/count/87]Cardiac disorders - Other, specify for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/3/count/9]Dehydration for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/30/count/90]Hyperglycemia for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/31/count/93]Hypertriglyceridemia for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/32/count/96]Hypocalcemia for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/33/count/99]Hypokalemia for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/34/count/102]Hyponatremia for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/35/count/105]Musculoskeletal and connective tissue disorder - Other, specify for NCT00003782 for E3 in NCT00003782 [clinicaltrials_resource:NCT00003782/serious_events/36/count/108]
group [clinicaltrials_vocabulary:group]
Doxorubicin + Docetaxel + Cyclophosphamide [clinicaltrials_resource:NCT00003782/group/E3]
Doxorubicin + Docetaxel + Cyclophosphamide
Bio2RDF identifier
NCT00003782/group/E3
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00003782/group/E3
group id [clinicaltrials_vocabulary:group-id]
description
Doxorubicin + Docetaxel + Cyclophosphamide
@en
identifier
clinicaltrials_resource:NCT00003782/group/E3
title
Doxorubicin + Docetaxel + Cyclophosphamide
@en
type
label
Doxorubicin + Docetaxel + Cyclophosphamide [clinicaltrials_resource:NCT00003782/group/E3]
@en